[Special Stock] Kumho HT Rises on Expectations of Moderna COVID-19 Vaccine Link from Subsidiary

[Asia Economy Reporter Minwoo Lee] Kumho HT's stock price is on the rise. This appears to be due to the highlighted connection with its subsidiary Dynona following Moderna's announcement of a large-scale supply plan for COVID-19 vaccines targeting adolescents.

As of 11:04 AM on the 4th, Kumho HT's stock price recorded 3,135 KRW, up 4.5% from the previous day. The news of Moderna's COVID-19 vaccine supply seems to have acted as a positive factor due to the association with its subsidiary Dynona, which is developing COVID-19 treatments.

According to major foreign media on the 3rd (local time), Moderna is expected to supply 100 million to 125 million doses of the new COVID-19 vaccine worldwide in the first quarter of next year. Of these, 85 million to 100 million doses will be provided to the United States, and the remaining 15 million to 25 million doses will be delivered to other countries. Moderna anticipates that the total global production volume for next year will be between 500 million and 1 billion doses.

Following this news, Entutek, classified as a Moderna-related stock, gained attention, and Dynona, in which Entutek recently invested shares, is also interpreted as having increased expectations for joint business. Entutek announced that it jointly appointed Robert Langer, a professor at the Massachusetts Institute of Technology (MIT) in the United States and a co-founder of Moderna, as a director and submitted a proposal for COVID vaccine distribution to Moderna. It is currently known that discussions with Moderna are underway regarding the quantity, schedule, and price for domestic distribution of the vaccine. Dynona is a specialized antibody treatment development company that recently received an investment of approximately 4.3 billion KRW through a paid-in capital increase from Entutek. It is currently listed on KONEX.

This content was produced with the assistance of AI translation services.